Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00349778 · ClinicalTrials.gov registry record · Phase 2
High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma
A Phase 2 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 102
- Enrollment target
NCT00349778: Completed Phase 2 study, sponsored by Stanford University.
NCT00349778 is a Phase 2 study that has completed, run by Stanford University. The registered enrollment target is 102 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (23% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00349778, a Phase 2 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 102 participants
- Enrollment target
Study Summary
This study uses a sequence of high-dose chemotherapy drugs and a stem cell transplant to treat multiple myeloma. The study is being performed to evaluate the efficacy and side effects of treatment. Specifically, the study is designed to reduce the risk of interstitial pneumonitis.
Primary Outcome
Pulmonary toxicity was assessed as the incidence of interstitial pneumonitis.
Interventions
- DRUG Cyclophosphamide
- DRUG Melphalan
- DRUG Etoposide
- DRUG Carmustine
- DRUG Filgrastim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2006-08 |
| Est. Completion | 2010-04 |
| Phase | Phase 2 |
What the finished NCT00349778 record still lists
NCT00349778 is an interventional study that assigns participants to a tested intervention. The registered 102 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (23% lower).
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00349778 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00349778 about?
NCT00349778 is a clinical study titled "High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma". This study uses a sequence of high-dose chemotherapy drugs and a stem cell transplant to treat multiple myeloma. The study is being performed to evaluate the efficacy and side effects of treatment. Specifically, the study is designed to reduce the risk of interstitial pneumonitis.
What is the current status of trial NCT00349778?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 102 participants. The study started on 2006-08. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00349778?
The interventions under investigation include: Cyclophosphamide (DRUG), Melphalan (DRUG), Etoposide (DRUG), Carmustine (DRUG), Filgrastim (DRUG).
Who is sponsoring clinical trial NCT00349778?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00349778's enrollment target sits among peer trials
102 668th of 2000 higher than 1,329 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03704662 · 102 participants · NA
Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma
- NCT04174742 · 102 participants
Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer
- NCT04275362 · 102 participants
Gait Analysis of a Lateral-Pivot Design Total Knee Replacement
- NCT04541082 · 102 participants · Phase 1
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia